Changes in invasive pneumococcal disease in the paediatric population in the second COVID-19 pandemic year

This study was funded by the Carlos III Health Institute of Madrid (ISCIII; PI17/00337) and the Catalan Agency for the Management of University Research Grants (AGAUR; grant numbers 2017/SGR 1342 and 2021/SGR 00742).

Bibliographic Details
Authors: Izquierdo, Conchita, Ciruela, Pilar, Soldevila, Núria, Garcia-Garcia, Juan-Jose, Gonzalez-Peris, Sebastia, Diaz Conradi, Alvaro, VIÑADO, BELEN, de Sevilla, Mariona F, Moraga Llop, Fernando, Muñoz-Almagro, Carmen, Domínguez, Angela, Barcino Working Group
Format: article
Publication Date:2023
Country:España
Institution:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repository:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:20.500.12328/3876
Online Access:http://hdl.handle.net/20.500.12328/3876
https://dx.doi.org/10.3390/vaccines11101548
Access Level:Open access
Keyword:Impacte de la COVID-19
Malaltia pneumocòcica invasiva
Vacuna antipneumocòcica conjugada 13-valent
Mesures no farmacèutiques
Impacto de la COVID-19
Enfermedad neumocócica invasiva
Vacuna neumocócica conjugada de 13 valencias
Medidas no farmacéuticas
Impact of COVID-19
Invasive pneumococcal disease
Pneumococcal 13-valent conjugate vaccine
Non-pharmaceutical measures
61
Description
Summary:This study was funded by the Carlos III Health Institute of Madrid (ISCIII; PI17/00337) and the Catalan Agency for the Management of University Research Grants (AGAUR; grant numbers 2017/SGR 1342 and 2021/SGR 00742).

Similar Items